-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Acurx Pharmaceuticals (NASDAQ:ACXP) Receives New Coverage From Analysts at HC Wainwright
Acurx Pharmaceuticals (NASDAQ:ACXP) Receives New Coverage From Analysts at HC Wainwright
HC Wainwright initiated coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) in a report released on Monday morning, The Fly reports. The firm issued a buy rating and a $14.00 price objective on the stock.
Separately, Alliance Global Partners started coverage on shares of Acurx Pharmaceuticals in a report on Thursday, October 20th. They issued a buy rating on the stock.
Get Acurx Pharmaceuticals alerts:Acurx Pharmaceuticals Stock Down 1.6 %
Acurx Pharmaceuticals stock opened at $3.77 on Monday. Acurx Pharmaceuticals has a 52 week low of $2.33 and a 52 week high of $4.89. The firm's 50-day simple moving average is $3.19 and its 200 day simple moving average is $3.48. The firm has a market capitalization of $43.71 million, a PE ratio of -3.52 and a beta of -0.73.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) last released its earnings results on Monday, November 14th. The company reported ($0.32) earnings per share (EPS) for the quarter.Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Semmax Financial Advisors Inc. increased its position in Acurx Pharmaceuticals by 365.5% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 5,879 shares of the company's stock worth $28,000 after purchasing an additional 4,616 shares in the last quarter. Castle Wealth Management LLC acquired a new stake in Acurx Pharmaceuticals in the second quarter valued at approximately $49,000. BlackRock Inc. grew its position in Acurx Pharmaceuticals by 149.8% in the first quarter. BlackRock Inc. now owns 16,699 shares of the company's stock valued at $55,000 after acquiring an additional 10,014 shares in the last quarter. Finally, Armistice Capital LLC acquired a new stake in Acurx Pharmaceuticals in the third quarter valued at approximately $3,198,000. Institutional investors and hedge funds own 3.03% of the company's stock.
About Acurx Pharmaceuticals
(Get Rating)
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
Featured Stories
- Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
HC Wainwright initiated coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) in a report released on Monday morning, The Fly reports. The firm issued a buy rating and a $14.00 price objective on the stock.
据The Fly报道,HC Wainwright在周一上午发布的一份报告中发起了对Acurx制药(纳斯达克:ACXP-GET评级)股票的报道。该公司对该股发布了买入评级和14.00美元的目标价。
Separately, Alliance Global Partners started coverage on shares of Acurx Pharmaceuticals in a report on Thursday, October 20th. They issued a buy rating on the stock.
另外,Alliance Global Partners在10月20日星期四的一份报告中开始报道Acurx制药公司的股票。他们对这只股票发布了买入评级。
Acurx Pharmaceuticals Stock Down 1.6 %
Acurx制药类股下跌1.6%
Acurx Pharmaceuticals stock opened at $3.77 on Monday. Acurx Pharmaceuticals has a 52 week low of $2.33 and a 52 week high of $4.89. The firm's 50-day simple moving average is $3.19 and its 200 day simple moving average is $3.48. The firm has a market capitalization of $43.71 million, a PE ratio of -3.52 and a beta of -0.73.
Acurx制药公司的股票周一开盘报3.77美元。Acurx PharmPharmticals的52周低点为2.33美元,52周高点为4.89美元。该公司的50日简单移动均线切入位为3.19美元,200日简单移动均线切入位为3.48美元。该公司市值为4,371万美元,市盈率为-3.52,贝塔系数为-0.73。
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors and hedge funds have recently modified their holdings of the stock. Semmax Financial Advisors Inc. increased its position in Acurx Pharmaceuticals by 365.5% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 5,879 shares of the company's stock worth $28,000 after purchasing an additional 4,616 shares in the last quarter. Castle Wealth Management LLC acquired a new stake in Acurx Pharmaceuticals in the second quarter valued at approximately $49,000. BlackRock Inc. grew its position in Acurx Pharmaceuticals by 149.8% in the first quarter. BlackRock Inc. now owns 16,699 shares of the company's stock valued at $55,000 after acquiring an additional 10,014 shares in the last quarter. Finally, Armistice Capital LLC acquired a new stake in Acurx Pharmaceuticals in the third quarter valued at approximately $3,198,000. Institutional investors and hedge funds own 3.03% of the company's stock.
机构投资者和对冲基金最近调整了对该股的持有量。Semmax金融顾问公司在第二季度将其在Acurx制药公司的持仓增加了365.5%。Semmax Financial Advisors Inc.现在持有该公司5,879股股票,价值28,000美元,该公司在上个季度又购买了4,616股股票。Castle Wealth Management LLC在第二季度收购了Acurx制药公司的新股份,价值约4.9万美元。今年第一季度,贝莱德在艾柯克制药的持仓增加了149.8%。贝莱德股份有限公司在上个季度增持了10,014股后,现在持有16,699股该公司股票,价值55,000美元。最后,停战资本有限责任公司在第三季度收购了Acurx制药公司的新股份,价值约为319.8万美元。机构投资者和对冲基金持有该公司3.03%的股票。
About Acurx Pharmaceuticals
关于Acurx制药公司
(Get Rating)
(获取评级)
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections.
Acurx制药公司是一家临床阶段的生物制药公司,开发用于治疗细菌感染的抗生素。它的主要候选抗生素是ibezapolstat,这是一种新的作用机制,针对的是聚合酶IIIC酶,该酶已经完成了治疗艰难梭菌感染的IIa期临床试验。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- 免费获取StockNews.com关于Acurx制药的研究报告(ACXP)
- 如果马斯克退出Twitter,特斯拉的股价会上涨吗?
- 2023年值得关注的5个下跌但不是下跌的股票
- Chewy能否在2023年获得两位数的增长?
- 礼来公司预计将实现持久增长,尽管面临眼前的挑战
- Madrigal制药公司的股票在一天内上涨了200%,原因如下
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Acurx制药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acurx制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧